Table 1.
Median age, y (range) | 59 (39–87) | P (progression-free survival) |
Median observation time of patients alive, mo (range) | 67 (8–153) | |
FIGO Stage | n (%) | |
IIC | 8 (7.5) | 0.2095 |
IIIA | 3 (2.8) | |
IIIB | 2 (1.9) | |
IIIC | 69 (64.5) | |
IV | 25 (23.4) | |
Histology | ||
Serous-papillary | 81 (75.7) | 0.0071 |
Endometrioid | 13 (12.2) | |
Clear cell | 10 (9.4) | |
Mucinous | 3 (2.8) | |
Disease | ||
Ovarian | 99 | |
Primary peritoneal | 7 | |
Primary fallopian tube | 1 | |
Grading | ||
G1 + G2 | 26 (24.3) | 0.6096 |
G3 | 81 (75.7) | |
Ascites volume | ||
≤500 mL | 43 (40.2) | 0.0014 |
>500 mL | 54 (50.5) | |
Unknown | 10 (9.3) | |
Residual tumor | ||
≤1 cm | 62 (57.9) | 0.0191 |
>1 cm | 43 (40.2) | |
Unknown | 2 (1.9) | |
Chemotherapy type | ||
Adjuvant | 107 (100.0) | |
Chemotherapy | ||
Taxane/platinum | 101 (94.3) | |
Cytoxan/platinum | 3 (2.8) | |
Platinum only | 2 (1.9) | |
Taxane | 1 (0.9) |